A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects.

Trial Profile

A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2012

At a glance

  • Drugs Evacetrapib; Ketoconazole
  • Indications Atherosclerosis; Dyslipidaemias
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 21 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 11 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top